Sachin Jain, MD, MBA, FACP, president and CEO at SCAN Group and SCAN Health Plan, discusses how data can help ensure that vulnerable populations aren't harmed by value-based payment models.
Sachin Jain, MD, MBA, FACP, is the president and CEO at SCAN Group and SCAN Health Plan.
Transcript:
The paper you co-authored discussed the need to ensure that value-based payment models do not create incentives that work against vulnerable populations. How can data help overcome this problem?
Jain: Yeah. Ultimately, at the foundation of this concern is risk adjustment. I think there's always an unintended consequence when you introduce a payment model that rewards organizations for managing health care utilization, there's always a risk that organizations will selectively apply those payment models to certain populations, unless, of course, they're rewarded for actually taking on that higher degree of complexity. Of course, it's very hard to identify that complexity, oftentimes, when we don't actually have the data that you need to have to appropriately risk adjust or identify cohorts of populations that could benefit from more intensive services and that warrant higher levels of reimbursement. With a better core of data, there's opportunities to, I think, create a higher degree of specificity around who actually exists within a population, and then pay organizations accordingly.
I think one of the areas where we've seen real challenges with this is actually the Medicare Advantage star rating system, where you're rewarded for completing a number of preventative screenings on patients as well as providing certain patient experience levels. Ultimately, some populations are harder to serve than others, but there's not a lot of adjustment for that in the formulas that calculate those star ratings. So, while the star ratings are directionally fantastic and are appropriate, they introduce this challenge of potentially rewarding organizations for actually serving healthier populations. Again, I think we have an opportunity to do better and a better core of data could actually help us do that.
NGS-Based Test Accurately Detects Post–Allo-HSCT Relapse in AML, MDS
February 21st 2025The next-generation sequencing (NGS)–based AlloHeme test accurately predicted relapse following allogeneic hematopoietic stem cell transplantation (allo-HSCT) in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS).
Read More
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
Prostate Cancer Studies Show Why Personalized Treatment, Trial Diversity Matter, Dorff Says
February 21st 2025Tanya B. Dorff, MD, medical oncologist and professor in City of Hope’s Department of Medical Oncology & Therapeutics Research, was a discussant for the TALAPRO-2 and STOPCAP trials at the opening session of ASCO GU.
Read More
5 Key Health Care Moments During President Trump's First Month Back in Office
February 21st 2025President Donald J. Trump pushed for significant health care changes during his first month back in office, through executive orders affecting managed care, drug pricing, and clinical trial diversity guidance.
Read More